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Abstract 
Tumour heterogeneity poses a distinct obstacle to therapeutic intervention.  While the 
initiation of tumours across various physiological systems is frequently associated 
with signature mutations in genes that drive proliferation and bypass senescence, 
increasing evidence suggests that tumour progression and clonal diversity is driven at 
an epigenetic level.  The tumour microenvironment plays a key role in driving 
diversity as cells adapt to demands during tumour growth, and is thought to drive 
certain subpopulations back to a stem cell-like state.  This stem cell-like phenotype 
primes tumour cells to react to external cues via the use of developmental pathways 
that facilitate changes in proliferation, migration, and invasion. Because the 
dynamism of this stem cell-like state requires constant chromatin remodelling and 
rapid alterations at regulatory elements, it is therefore of great therapeutic interest to 
identify the cell-intrinsic factors that confer these epigenetic changes that drive 
tumour progression.  The Nuclear factor one (NFI) family are transcription factors 
that play an important role in the development of many mammalian organ systems.  
While all four family members have been shown to act as both oncogenes and tumour 
suppressors across various cancer models, evidence has emerged associating them as 
key epigenetic regulators during development and within tumours. Notably, NFIs 
have also been shown to regulate chromatin accessibility at distal regulatory elements 
that drive tumour cell dissemination and metastasis. Here we summarise the role of 
the NFIs in cancer, focusing largely on the potential mechanisms associated with 
chromatin remodelling and epigenetic modulation of gene expression. 
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Introduction  
Epigenetics has historically been defined as heritable cellular phenotypes of 
organisms that are independent of alterations in DNA sequence, however as the term 
has continued to evolve, it is now used more to describe changes in cellular and 
molecular phenotype that are associated with alterations to chromatin structure and 
accessibility
1, 2
.  A major substrate of epigenetic change is chromatin, the 
macromolecular complex made up of DNA and histone proteins. Chromatin can be 
modified by four distinct mechanisms; these are DNA methylation, histone 
modification, nucleosome remodelling and RNA-mediated targeting.  While 
epigenetic processing was first described as an important process in development
3
, its 
misregulation is now thought to also be a key component in driving cancer formation 
and tumour progression
4, 5
.  For example, factors associated with tumour progression 
such as aging
6
, chronic inflammation
7
 and environmental exposure such as to 
cigarette smoke
8
 alter the epigenome of cells. 
 
One key aspect associated with cancer progression is tumour heterogeneity
9
.  This 
heterogeneity is not only defined by the various cell types often found within tumours 
(fibroblasts, endothelial cells, pericytes, and immune cells), but also at the genetic and 
phenotypic level within individual cancer cells
10
. Despite many tumours originating 
via irreversible mutations in oncogenes and tumour suppressors derived from a single 
cell, many cancers display large levels of clonal diversity
11
. While the mechanisms 
behind tumour heterogeneity at the genetic and phenotypic level are continually being 
defined, there is a clear epigenetic component that drives this process
12
.  The highly 
proliferative nature of many malignancies makes the tumour microenvironment very 
dynamic during growth and as such, cells must continuously adapt to environmental 
stressors.  Conditions such as nutrient deprivation, hypoxia, immune responses, and 
even treatments aimed at destroying tumours have been shown to induce considerable 
changes in cancer cell DNA methylation status and chromatin remodelling
13, 14
.  Cross 
talk between cellular populations (both cancer and other stromal populations), either 
through direct interaction, or via secretory factors, can also induce changes in cell 
motility and proliferation at an epigenetic level.  An interesting observation 
commonly associated with cellular invasion is the idea that many cancer cells undergo 
a process of de-differentiation to attain a stem cell like phenotype
15, 16
.  Such a cell 
state is extremely dynamic and primed to respond to external cues, allowing it to 
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quickly alter its proliferative and migratory characteristics throughout various 
developmental stages
12, 17
. This dynamism relies heavily on chromatin remodelling 
and changes to histone structure and function, through the combinatorial effect of a 
myriad of histone modifications that can be rapidly altered to facilitate immediate and 
reversible changes to gene expression
18
.   
 
Micro RNAs (miRNA) are another key epigenetic regulator that potentiates tumour 
progression.  They can act as either oncogenes or tumour suppressors and as such, can 
be regulated in a manner that their expression is increased or decreased via 
transcriptional regulation.  There are various mechanisms contributing to miRNA 
deregulation in cancer cells
19
.  Interestingly, while the regulation of cancer cell 
phenotypes via miRNAs is often an intrinsic cellular process, there are various 
mechanisms in which miRNAs can be secreted in the microenvironment to induce 
autocrine and paracrine effects on other tumour cell populations
19
.  They can also play 
a distal role in regulating tumour angiogenesis, immunophenotype, and extracellular 
matrix (ECM) remodelling
19, 20
.  Deregulation of miRNAs within stromal cell 
populations has also been shown to play a large role in promoting initial tumour 
formation and progression
20
, while other microenvironmental factors such as hypoxia, 
nutrient deprivation, and increased acidity also drive aberrant miRNA expression in 
cancer cells 
21, 22
. 
 
Tumour heterogeneity has a clear therapeutic impact
23-25
.  The clonal diversity 
observed in many developed tumours is vast and frequently small clonal subsets will 
confer selective advantages that drive tumour progression or remain refractory to 
therapies that are effective against the majority of cells in the tumour. It is clear that 
modulation of the genome at the epigenetic level plays a major role in heterogeneity 
and is therefore of great therapeutic interest to identify key regulators that confer 
these epigenetic changes throughout tumour progression.   
 
This review will focus one such family of regulators, the NFIs, and their role in 
tumour progression. First described as a host protein required for adenovirus 
replication (Nagata et al., 1982), there have been four NFI transcription factors 
identified in vertebrates, NFIA, NFIB, NFIC and NFIX
26, 27
. NFIs are 
developmentally important proteins that in broad terms drive progenitor cell 
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differentiation within the central nervous system
28-30
, lung
31, 32
 and muscle
33, 34
. After 
early embryonic and postnatal development, NFIs continue to have important roles in 
regulating progenitor cell biology. In adult progenitors cells, within neural tissue, the 
skin, and skeletal muscle, NFIs promote differentiation
35, 36
 but also regulate the 
balance between cell-cycle entry and exit
36-38
, and thereby regulate the homeostasis 
that exists between progenitor pool expansion and tissue regeneration. NFIs have also 
been established as key tumour suppressors and oncogenes across a range of cancers, 
with recent evidence suggesting that they may function as key drivers of tumour 
progression by coordinating changes in the epigenome
39
.  
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NFIs as epigenetic regulators  
Transcription factors are traditionally defined by their ability to coordinate gene  
expression by binding directly to regulatory regions within DNA alone, or via protein  
interactions with transcription co-factors that bind DNA indirectly through interaction  
with transcription factors at cis-regulatory sites.  NFIs for example, can both activate  
or repress gene expression by direct binding to the DNA dyad symmetric consensus  
site or half-site sequence TTGGC(N5)GCCAA on double stranded DNA
40-42
, forming  
homodimers or heterodimers with other proteins.  While this is a key feature of  
transcription factors, evidence reveals that many families are able to alter gene  
expression by modulating chromatin structure directly through nucleosome  
remodelling, or indirectly via interactions with, or the regulation of, epigenetic  
modifiers.  We argue that this may also be true of NFI family members, consistent  
with a number of studies demonstrating that NFIs interact with chromatin and  
chromatin regulators in a variety of ways. Moreover, recent chromatin  
immunoprecipitation sequencing (ChIP-seq) and RNA sequencing (RNA-seq)  
experiments suggest that the net effect of these NFI-chromatin interactions may be to  
increase chromatin accessibility and gene expression 
39, 43
.  
  
NFI activity generally correlates with increased expression of their target genes and  
are associated with higher levels of active promoter methylation marks such as  
H3K4me3 and H3K36me3, implicating them predominantly as activators of  
transcription
44
.  The first evidence implicating the NFI family acting in a  
transcriptionally independent manner found that they were able to bind to GCCAAT  
recognition sites and serve as initiation factors in DNA replication
45
.  Moreover, early  
structural analysis of NFIs identified their potential for chromatin regulation as they  
contained a trans-activation domain that interacts with histone H1 and H3
46, 47
.    
Further functional analysis demonstrated that NFIs were able to alter the interaction  
of reconstituted nucleosomal cores with DNA in vitro in a growth factor-dependent  
manner
47
. In vivo evidence also revealed that NFIs are able to alter native chromatin  
structure at yeast origins of replication
48
 and other promoter regions through direct  
interaction with histone proteins
49
.  NFIs were also shown to activate simian virus 40  
(SV40) DNA replication in vivo by interacting directly with histone H3 and relieving  
nucleosomal repression at the SV40 origin
50
. Indeed, there are many other examples  
of NFI directly interacting with the nucleosomal architecture.   Studies in yeast cells  
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for example, show that NFI was able to delimit chromatin domain boundaries by 
binding histone H3, thereby preventing epigenetic teleomeric silencing by forming a 
partition between the gene and telomere and blocking silent information regulator 
(SIR) proteins involved in the de-acetylation of histone tails
51
.  More recently, 
genome wide mapping analysis of NFI DNA binding sites within mouse embryonic 
fibroblast confirms that there is a clear association between NFI and histone H3
44
. 
Consistent with this, NFI globally associates with chromatin domain boundaries, 
separating permissive and silent chromatin markers as defined by localisation with 
H3K27me3 and H3K36me3 boundaries of opposite polarities, and they were further 
found to directly interact with positioned nucleosomes
43
.   
 
Crucially, NFIs have also been shown to interact with chromatin in human cells.  
NFIs are able to prevent the silencing of transgenes upon chromosomal integration in 
a histone dependant manner, however they were unable to activate transcription alone 
in HEK293 cells
52
. Studies performed in HeLa cells investigating mechanisms 
underlying the boundaries between euchromatic (active, permissive chromatin) and 
heterochromatic (silent, condensed chromatin) domains confirmed that NFI proteins, 
or fusions containing the histone binding domain of NFIs, can partition two genes 
colocalized at a telomeric locus into active and inactive chromatin structures
53
.  These 
findings suggest a mechanism whereby NFI interacts directly with nucleosomes in a 
transcriptional independent manner to establish a chromosomal structure that blocks 
silencing signals emanating from the telomere, while maintaining a permissive 
chromatin state to allow for increased gene expression within these regions. It also 
provides further mechanistic evidence to explain the previous findings that NFIs can 
induce a permissive chromatin state to reverse chromatin-mediated gene silencing 
without being able to activate transcription of these genes alone
52
. 
 
In depth analysis of NFI interactions with chromatin and their role in remodelling 
have also been performed using long terminal repeat (LTR) regulatory sequences of 
the mouse mammary tumour virus (MMTV) (for an in depth review on this, see
54
).  
NFI-binding sites were found on B nucleosomes in the MMTV promoter in the 1980s, 
with research showing that there is a functional synergism between NFI and the 
glucocorticoid receptor (GR) in binding to a chromatin template and activating the 
promoter, which was abrogated in a nucleosome depleted environment
55
.  Follow up 
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studies in this model system using linker-scanning mutants of transcription factor 
binding sites found that NFIs were required for hormone-dependent chromatin 
remodelling, as they found that binding site mutations substantially decreased 
hormone-mediated remodelling of nucleosome B and that NFI was also necessary for 
the association between the BRG1 chromatin remodelling complex and GR on the 
promoter in vivo
56
.  Studies into S. cerevisiae looking at minichromosomes assembled 
on MMTV LTR are consistent with a role for NFIs in chromatin remodelling, as they 
act as classical transcription factors in a relaxed chromatin context, whereas in a wild 
type chromatin confirmation, NFI cooperates with steroid hormone receptors to 
stabilize an open chromatin confirmation by interacting with the nucleosome
56
. 
Moreover, in vivo studies using Xenopus oocytes uncovered a role of NFIs in 
initiating nucleosome remodelling independent of these chromatin-remodelling 
complexes
57
. NFIs have also been shown to interact with Octamer Factor 1 (OCT1) 
and form a present chromatin structure through remodelling
58
. This study found that 
both transcription factors were able to bind to their cognate sites within the MMTV 
promoter to alter chromatin structure from randomly positioned nucleosomes to 
induce a partial translational positioning that enhances the hormone-induced response 
of the receptor and correlates with increased basal transcription
58
.  Overall these 
model systems have defined a clear role where NFIs can act in a transcriptionally 
independent manner to regulate gene expression by altering chromatin structure 
through direct remodelling and induce a permissive chromatin state via nucleosomal 
interaction. 
 
NFIs have also been shown to affect chromatin remodelling in a more indirect manner 
by regulating the expression of numerous chromatin-modifying genes and by 
interacting with chromatin modifiers.  The Enhancer of zeste homolog 2 (EZH2) is a 
histone-lysine N-methyltransferase enzyme that represses transcription by catalysing 
the addition of methyl groups to histone H3 at lysine 27. NFIB has been shown to 
directly repress EZH2 during development of the cerebral cortex to promote neurone 
differentiation
59
.  The genome-wide mapping study previously discussed by Pjanic 
and colleagues
43
 correlated NFI with histone methylation modifications H3K4me3 
and H3K36me3 at markers of transcribed genes and even outside annotated 
transcribed loci, suggesting NFIs may facilitate these modifications. NFIs have also 
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 9
been show to interact with histone deactylases such as BAF at various promoter  
regions
60, 61
 and other transcriptional activators such as BRG1
56
.    
  
  
Epigenetic mechanisms of NFIs in cancer  
In light of these findings, it is clear that the NFI family have dual functionality in  
acting as classical transcription factors, but also as epigenetic modifiers.  In addition  
to development and maintenance of normal cellular physiology, NFIs have been  
shown to act as tumour suppressors and oncogenes across a wide range of cancer  
types (see Table 1 for a brief overview).  Within the context of cancer, chromatin  
accessibility studies are regarded as one of the most relevant genomic characteristics  
that correlate with activity at specific loci, and efforts to characterize changes in  
global chromatin structure between normal cells, cancer cells and lines differing in  
metastatic potential have become a considerable focus of cancer research 
62-64
.  Recent  
high-impact studies examining NFIB function in small cell lung cancer (SCLC)  
suggest that in this context, NFIs might modify chromatin architecture in a manner  
that results in increased tumour heterogeneity
39, 65
.  The most prominent study  
implicating NFI as an epigenetic driver of cancer progression found that NFIB  
promotes metastasis through a wide spread increase in chromatin accessibility
39
.  In  
this study, primary and metastatic tumours were isolated from genetically engineered  
mice, and genome-wide characterization of chromatin accessibility (ATAC-seq) was  
used to identify global changes throughout the different tumours. These studies  
demonstrate that there was a dramatic increase in chromatin accessibility that occurs  
during malignant progression.  The most highly enriched motif identified between the  
differentially accessible regions was the binding site for the NFI family, with the  
hyper-accessible samples also showing genomic amplification of the NFIB locus.   
Crucially NFI motifs in hyper-accessible samples had increased promoter occupancy,  
depleted nucleosomes, and exhibited a significant change in local chromatin  
architecture, the maintenance of which was dependent on NFIB expression.  While  
the mechanistic basis of the NFIB driven hyperaccessibile chromatin state was not  
reported in this study, the data was suggestive of SCLCs containing a “preset”  
configuration during early malignant transformation that permits initial binding of  
these motifs following NFIB up regulation.  This proposed mechanism suggests an  
intrinsic NFI driven signal can promote metastasis irrespective of genetic mutation  
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and warrants further investigation into other cancer subtypes. Analysis of DNA foot-
printing showed NFIB had a long half-life upon binding to consensus sites and it was 
suggested that this long residency allows adaptation of nearby chromatin to enforce 
an opened architecture, which is further stabilized by binding of other motifs to the 
enriched regions in the newly open sites.  Analysis of NFIB interacting directly with 
histones H1 and H3 or recruiting chromatin-modifying complexes was not 
investigated but was suggested to potentially complement the study’s proposed 
mechanism. Further research investigating these potential interactions would provide 
a greater mechanistic insight of NFIs in remodelling chromatin within a cancer 
context, and may provide scope for therapeutic targets against chromatin modifiers. 
 
A potential tumour suppressor role has also been identified for NFIA and NFIC in 
breast cancer through the epigenetic repression of a disintegrin and metalloprotease 
domain-containing protein 12 (ADAM-12)
66
.  ADAM-12 levels in urine have been 
correlated with disease progression in breast and bladder cancer, have been shown to 
be up regulated in many cancers, and also promote cancer metastasis.  The chromatin 
modifier methyl CpG binding protein 2 (MeCP2) is a transcriptional repressor that is 
associated with DNA methylation, histone deacetylation, and with the recruitment of 
chromatin remodelling complexes
67-69
.  Ray and colleagues
66
 identified a novel 
interaction between NFIs with MeCP2 at Z-DNA elements of ADAM-12 to induce its 
repression.  Z-DNA forming regions and promoter sites for NFI have previously been 
highly correlated with the transcriptional start site of many genes
70
,  and this study 
demonstrated that the MeCP2-NFI interaction at Z-DNA elements is necessary for 
repression, and that MeCP2 deficiency in breast cancer cells results in ADAM-12 
overexpression and tumour progression
66
.  Another study focusing on the epigenetic 
regulation of the tumour suppressor gene hDAB2IP in prostate cancer lines found that 
there was an increase in acetylhistone H3 levels associated with the promoter in PCa 
prostate cancer lines
71
. ChIP assays identified several NFI binding motifs associated 
with this region, potentially implicating a functional role in nucleosomal binding of 
NFIs in this cancer context. 
 
In addition to altered expression, numerous examples of NFI fusion proteins have 
been reported in a number of cancer subtypes.  Cases have been documented across 
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acute erythroid leukaemia, adenoid cystic carcinomas, breast cancer, and pilocytic  
astrocytoma, all with different protein fusion targets
72-76
.  While the prevalence of  
such changes is well documented, the functional nature of these lesions has yet to be  
explored.  Consistently, NFIs as fusion proteins appear to increase the activity of their  
respective fusion partners’ downstream signalling pathways, but do not appear to  
effect NFI regulatory target gene expression
72, 73
.  Fusion proteins have been reported  
with transcription factors (NFIB-MYB), chromatin modifying complexes (NFIA- 
CBFA2T3), and kinases (NFIA-RAF1) and usually contain only a partial form of  
NFI
72, 74, 75
.  Studies discussed previously in this paper highlight NFIs role in forming  
a chromatin domain barrier/boundary that blocks propagation of silencing signals  
emanating from heterochromatic silent regions within the telomere
53
.  The formation  
of these domains allowed NFI to maintain a permissive open chromatin state upon  
binding to histone regions, which allowed for active gene expression within that area.  
Esnault and colleagues (2009) found that only the histone-binding domain of NFI was  
necessary to perform this function. They employed the use of NFI fusion proteins  
with GAL4 and found that they performed this barrier function irrespective of the  
reporter gene identity or its transcriptional orientation and distance from the promoter,  
and also did not affect genes adjacent to the telomere.  These findings highlight the  
potential of NFI genes implicated as fusion proteins in cancer to remodel chromatin  
areas in a transcriptionally independent manner and to allow a permissive open  
chromatin state for increased binding of their fusion counterpart to regulatory  
genomic regions.           
  
Conclusions  
Genome wide analysis of global changes in chromatin landscape and architecture  
within cancer is a relatively new field.  There is great scope for studies investigating  
NFIs as potential chromatin regulators at both a global and local level across various  
cancers, as they have clearly been implicated as epigenetic modifiers during  
development and homeostasis.  The study conducted by Denny and colleagues
39
, is  
one of the first showing that a single transcription factor is capable of inducing  
chromatin state changes globally upon high expression, and also highlights the  
capability of hyperaccessible genomic regions in driving a metastatic phenotype
39
.   
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The finding that there appears to be a ‘preset’ configuration in malignant transformed 
cells for the binding of NFI motifs to induce chromatin hyperaccessibility shows that 
NFIs are key in inducing the switch necessary for metastatic progression in SCLC. It 
is highly suggestive of a novel, pre-defined intrinsic mechanism in driving metastasis 
in cancer cells that occurs at an epigenetic level, as opposed to tumour cells 
progressing via the accumulation of genetic mutations from genomic instability.  
Given that this work only focused on SCLC, it remains to be determined if similar 
changes in chromatin accessibility driven by NFIs is relevant in other cancer 
subtypes, or whether other transcription factors are capable of a similar function.  
Certain events imposed on cells by the tumour microenvironment (hypoxia, nutrient 
deprivation, increased acidity etc.) are key drivers of tumour heterogeneity
12
 and may 
be capable of driving changes in NFI expression and as such, may have the potential 
of inducing this hyperaccessible state following increased NFI expression.  This 
warrants further investigation into the potential heterogeneity of NFI transcription 
factor expression and cellular function across various tumours, and whether the 
microenvironment is capable of altering NFI expression. 
 
Future studies using single cell sequencing approaches will provide improved 
resolution as to whether NFIs drive epigenetic changes uniformly across cellular 
populations, or if this differs vastly on a per cell basis. For example, there exists the 
potential for single cell ATAC-Seq technology as an approach for profiling single 
cells at an epigenetic level
77
.  Given the cell-cell variability within tumours and the 
potential for a pre-set epigenetic state to drive metastasis, this methodology may be 
useful in further uncovering epigenetic changes associated with heterogeneity and 
metastatic progression.  These data can be enhanced further by the addition of 
expression profiling of individual cells by Drop-Seq analysis, where thousands of 
single cells, originating from dissolved in vivo tissues are forced into miniscule 
droplets before RNA-Seq analysis
78
.  If this technology can further extend to ATAC-
Seq or histone modifications, it would become a useful tool in further defining 
epigenetic differences in heterogenous tumour populations. 
 
The mechanism through which NFIs promote chromatin accessibility in SCLC and 
potentially, other cancers, remains to be defined.  A fascinating proposition could be 
that like in normal cellular physiology, NFIs function to inhibit silencing signals 
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emanating from telomeric ends
51-53
. Telomeres and associated proteins form a unique 
DNA-protein structure that protects chromosome ends from being recognised as DNA 
double stranded breaks, and are well documented tumour suppressors
79
.  As 
mentioned, telomeres have previously been thought to regulate proximal gene 
expression, as the heterochromatic nature of their structure coupled with the 
recruitment of SIR and other histone deacetylase (HDAC) enzymes results in the 
short range spreading of a hypoacetylation signal
53
.  A recent study however, has 
demonstrated that chromosome looping can induce telomeric silencing up to 10 Mbs 
away from the telomere, implicating their role in the regulation of a large number of 
genes at each chromosomal end
80
.  The potential genes and the significance behind 
their regulation during homeostasis and within cancer has yet to be defined, however 
given NFIs previously defined mechanism, one would predict to see an increased 
accessibility of chromatin and expression of genes close to telomeric regions in SCLC 
if they displayed this functionality. Evaluation of existing ATAC-seq and RNA-seq 
datasets in SCLC
39
 could provide this answer. Given NFIs ability to affect chromatin 
structure in a multitude of ways however, it is important to consider that other 
mechanisms (both direct and indirect) may be key in driving this hyperaccessible 
phenotype. 
 
Research implicating the importance of epigenetics in cancer has made chromatin-
modifying enzymes an attractive therapeutic target.  Several HDAC and DNA 
methyltransferase (DNMT) inhibitors are undergoing clinical trial and are now 
recognised as effective and well-tolerated treatments both alone and in combination 
with other therapies
81-83
.  Transcription factors are notoriously difficult to target 
therapeutically, and despite recent advances
84
, targeting of NFI proteins may be 
challenging in certain tumour contexts. NFI members are very similar in terms of 
sequence homology and DNA binding and there are several documented cases where 
certain members act in opposite tumourigenic roles 
66, 85, 86
.  Given the extensive 
history of NFIs acting as chromatin regulators during development and homeostasis, 
studies investigating a similar role for NFIs within cancer may highlight potential 
therapeutic candidates downstream that may be targeted more effectively.  The 
potential for NFI to alter global chromatin architecture within a subset of cancers to 
drive metastasis may also a make it a great prognostic marker for tumour progression.  
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Table.1 NFI family in cancer 
Cancer type Gene Oncogene/Tumour suppressor Reference 
Acute erythroid 
leukaemia 
 
NFIA Oncogene, forms 
NFIA/CBFA2T3 fusion protein  
75
 
Adenoid cystic 
carcinomas 
NFIB Oncogene, forms a fusion protein 
with MYB oncogene 
72, 73
 
Breast cancer NFIA 
 
 
 
 
 
NFIB 
 
 
NFIC 
 
 
 
 
 
 
NFIX 
Oncogene and tumour suppressor, 
regulates SULT1A1 levels, 
increases cancer risk, drug 
resistance.  Inhibits ADAM12 
expression 
 
Oncogene, associated with HER2 
overexpression and survival.   
 
Tumour suppressor and oncogene, 
suppresses EMT, migration, and 
invasion through KLF4-E-cad 
axis.  Also regulates SULT1A1 
levels.  Inhibits ADAM12 
expression 
 
Oncogene, forms fusion protein 
with Mast kinase, promotes 
proliferation. 
66, 72, 76, 85-88
  
Cutaneous 
squamous cell 
carcinoma 
NFIB Tumour suppressor, targeted by 
onco-miR-365 
89
 
Cervical 
carcinoma 
NFIA
NFIB
NFIC
NFIX 
Oncogene, NFI-SKI interaction 
drives TGF-β inhibition in 
HPV16, drives tumour 
progression. 
 
90
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Diffuse gastric 
cancer 
NFIX  Tumour suppressor, NFIX 
potentially binds to CDH1 risk 
polymorphism. 
91
 
Oesophageal 
squamous cell 
carcinoma 
NFIA 
 
 
NFIX 
Oncogene, drives proliferation 
and migration 
 
Tumour suppressor, MIR-1290 
targets NFIX, promotes 
proliferation, invasion. 
92, 93
  
Glioblastoma NFIA 
 
 
 
NFIB 
Oncogene, down regulates P53, 
P21, and PAI1 to drive growth 
and migration. 
 
Tumour suppressor, associated 
with improved survival, ectopic 
expression inhibits 
tumourigenesis 
94, 95
 
Glioma  NFIA Oncogene, Inhibits p21 required 
for tumourigenisis 
96
 
Hepatocellular 
carcinoma 
NFIB Oncogene, up regulated in HCC 
and drives survival 
97
 
Lung 
adenocarcinoma 
NFIB Tumour suppressor, low 
expression associated with more 
aggressive subtype, poor survival 
98
 
Osteosarcoma NFIB Tumour suppressor, SNP 
rs7034162 in NFIB significantly 
associated with lower NFIB 
expression, increased metastasis 
 
99
 
Pilocytic 
Astrocytoma 
NFIA Oncogene, NFIA:RAF1 fusion 
activates the MAPK pathway 
74
 
Small cell lung 
carcinoma 
NFIB Oncogene, increases chromatin 
accessibility, marks metastatic 
disease 
39, 65, 100
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Abbreviations  
  
ADAM12  Disintegrin and Metalloprotease domain-containing protein 12 
ATAC-seq Assay for Transposase-Accessible Chromatin with high throughput 
sequencing 
ChIP-seq Chromatin immunoprecipitation sequencing 
DNMT DNA methyltransferase 
ECM Extracellular matrix 
EZH2  Ehancer of Zeste Homolog 2 
GR Glucocorticoid Receptor 
HDAC Histone Deacetylase 
LTR Long Terminal Repeats 
MeCP2  Methyl CpG binding protein 2 
miRNA micro RNA 
MMTV Mouse Mammary Tumour Virus 
NFI Nuclear Factor One 
NFIA Nuclear Factor One A 
NFIB Nuclear Factor One B  
NFIC Nuclear Factor One C 
NFIX Nuclear Factor One X 
OCT1a Octamer Factor 1 
RNA-seq RNA sequencing 
SCLC Small Cell Lung Cancer 
SV40 Simian Virus 40 
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